| Autor: |
Mahatma MM; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK., Jayasuriya RL; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK., Hughes D; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Hoggard N; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield S10 2RX, UK., Buckley SC; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Gordon A; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Hamer AJ; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Tomouk MW; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Kerry RM; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Eastell R; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK; Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield S10 2RX, UK., Wilkinson JM; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK; Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield S10 2RX, UK. Electronic address: j.m.wilkinson@sheffield.ac.uk. |
| Abstrakt: |
Competing Interests: RE declares grants from Alexion, Amgen, Immunodiagnostic Systems, Roche, and Nittobo; and personal fees from Amgen, Immunodiagnostic Systems, Roche, GlaxoSmithKline Nutrition, Mereo, Sandoz, Nittobo, AbbVie, Samsung, Haoma Medica, Elsevier, CL Bio, Foundation for the National Institutes of Health, Viking, University of California San Francisco, Biocon, and Lyramid, outside the submitted work. All authors report a grant from Amgen, in relation to the work discussed here. |
